Thermo Fisher Scientific Inc.
TMO · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 4.64 | -2.75 | -3.24 | 1.56 |
| FCF Yield | 3.66% | 3.38% | 3.20% | 2.67% |
| EV / EBITDA | 19.28 | 20.83 | 20.38 | 24.63 |
| Quality | ||||
| ROIC | 8.03% | 8.02% | 9.00% | 10.68% |
| Gross Margin | 41.34% | 40.12% | 42.33% | 50.07% |
| Cash Conversion Ratio | 1.37 | 1.40 | 1.32 | 1.23 |
| Growth | ||||
| Revenue 3-Year CAGR | -1.53% | 3.01% | 11.71% | 15.36% |
| Free Cash Flow Growth | 4.91% | 0.23% | -1.55% | 3.01% |
| Safety | ||||
| Net Debt / EBITDA | 2.44 | 2.53 | 2.31 | 2.66 |
| Interest Coverage | 4.63 | 4.99 | 11.74 | 19.25 |
| Efficiency | ||||
| Inventory Turnover | 5.05 | 5.04 | 4.60 | 3.88 |
| Cash Conversion Cycle | 109.50 | 113.82 | 108.35 | 123.98 |